NCT04711135 2026-02-12NETTER-PAdvanced Accelerator ApplicationsPhase 2 Active not recruiting11 enrolled 14 charts 2 FDA
NCT05636618 2025-11-24Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine TumorsPerspective TherapeuticsPhase 1/2 Recruiting260 enrolled
NCT00874614 2020-02-20A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/ParagangliomaMolecular Insight Pharmaceuticals, Inc.Phase 2 Unknown74 enrolled 10 charts 2 FDA
NCT00458952 2016-07-13Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/ParagangliomaMolecular Insight Pharmaceuticals, Inc.Phase 1/2 Completed24 enrolled 8 charts
NCT00339131 2011-10-12ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic CarcinoidMolecular Insight Pharmaceuticals, Inc.Phase 1 Completed24 enrolled